<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307605</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 35/10</org_study_id>
    <secondary_id>SWS-SAKK-35-10</secondary_id>
    <secondary_id>2010-021253-39</secondary_id>
    <secondary_id>CELGENE-SWS-SAKK-35/10</secondary_id>
    <nct_id>NCT01307605</nct_id>
  </id_info>
  <brief_title>Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma</brief_title>
  <official_title>Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in&#xD;
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer&#xD;
      cells and help kill them or carry cancer-killing substances to them. Lenalidomide may stop&#xD;
      the growth of non-Hodgkin lymphoma by blocking blood flow to the cancer. It is not yet known&#xD;
      whether rituximab is more effective when given alone or together with lenalidomide in&#xD;
      treating patients with follicular lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying rituximab to see how well it works&#xD;
      compared with giving rituximab together with lenalidomide in treating patients with&#xD;
      previously untreated follicular lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the activity of rituximab in combination with lenalidomide versus rituximab&#xD;
           alone in patients with previously untreated follicular lymphoma in need of therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to grade of disease&#xD;
      (grades 1 or 2 vs 3a), presence of bulky disease (defined as masses ≥ 6 cm) (yes vs no),&#xD;
      Follicular Lymphoma International Prognostic Index score (1 or 2 vs ≥ 3), and participating&#xD;
      centers. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm A: Patients receive rituximab IV on day 1 in weeks 1, 2, 3, 4 and weeks 12, 13, 14,&#xD;
           15 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm B: Patients receive rituximab IV as in arm A. Patients also receive oral&#xD;
           lenalidomide once daily, starting 14 days before first rituximab administration and last&#xD;
           until 14 days after the last rituximab administration, in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      All patients undergo restaging at week 10. Patients who show less than a minimal response&#xD;
      (i.e., reduction of more than 25% in sum of product of diameters [SPD]) are off study&#xD;
      treatment and transferred to the follow-up phase. Patients undergo a second restaging in week&#xD;
      23.&#xD;
&#xD;
      Some patients may undergo biopsies and blood and bone marrow sample collection periodically&#xD;
      for biomarker studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 20 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2011</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Actual">June 20, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>at week 23</time_frame>
    <description>The evaluation of CR is outlined in Appendix 1 Criteria for Evaluation of Response in Non-Hodgkin's Lymphoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response (OR)</measure>
    <time_frame>within 24 weeks</time_frame>
    <description>OR is defined as either:&#xD;
the disappearance of all evidence of disease (CR or CRu)&#xD;
the regression of measurable disease with no new sites (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall response (OR)</measure>
    <time_frame>within 12 weeks</time_frame>
    <description>OR is defined as either:&#xD;
the disappearance of all evidence of disease (CR or CRu)&#xD;
the regression of measurable disease with no new sites (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until disease progression, for up to 10 years after randomization</time_frame>
    <description>PFS will be calculated from randomization until the first event of interest:&#xD;
disease progression or relapse according to criteria of Cheson et a.l 1999&#xD;
death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first off-trial anti-lymphoma therapy</measure>
    <time_frame>until off-trial therapy administration, for up to 10 years after randomization</time_frame>
    <description>This will be calculated from randomization until the start of the first off-trial anti-lymphoma treatment.&#xD;
Patients not receiving any off-trial anti-lymphoma treatment will be censored at the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 6 months for up to 10 years after randomization</time_frame>
    <description>OS will be calculated from randomization until death. Patients not experiencing an event will be censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, including laboratory abnormality assessments and vital signs</measure>
    <time_frame>from inclusion until 30 days after treatment discontinuation</time_frame>
    <description>This will be evaluated using the NCI CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab plus Lenalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Rituximab (MabThera)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.</description>
    <arm_group_label>Rituximab plus Lenalidomide</arm_group_label>
    <other_name>Lenalidomide (Revlimid)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed follicular lymphoma&#xD;
&#xD;
               -  Stage III or IV disease OR stage II disease not suitable for radiotherapy&#xD;
&#xD;
               -  Grades 1, 2, or 3a disease&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Patients in need of systemic therapy, meeting at least 1 of the following criteria:&#xD;
&#xD;
               -  Symptomatic enlarged lymph nodes, spleen, or other lymphoma manifestations&#xD;
&#xD;
               -  Bulky disease ≥ 6 cm in long diameter&#xD;
&#xD;
               -  Clinically significant progression over at least 6 months of any tumor lesion&#xD;
&#xD;
               -  Anemia (hemoglobin &lt; 100 g/L) or thrombocytopenia (platelet count &lt; 100 x 10^9/L)&#xD;
                  due to lymphoma&#xD;
&#xD;
               -  Clinically significant progressive decrease in hemoglobin or platelet count due&#xD;
                  to lymphoma&#xD;
&#xD;
               -  B-symptoms, weight loss &gt; 10% within the past 6 months, drenching night sweats,&#xD;
                  or fever &gt; 38°C not due to infection&#xD;
&#xD;
          -  At least one two-dimensionally measurable lesion with longest transverse diameter &gt; 10&#xD;
             mm&#xD;
&#xD;
          -  Paraffin-embedded tumor tissue available&#xD;
&#xD;
          -  No known CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  EF ≥ 50% for patients with a history of cardiac disease or older than 70 years&#xD;
&#xD;
          -  Neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless due to Gilbert syndrome)&#xD;
&#xD;
          -  ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 4 weeks prior to, during, and for 12&#xD;
             months after completion of study therapy&#xD;
&#xD;
          -  Must be compliant and geographically proximal to allow for proper staging and&#xD;
             follow-up&#xD;
&#xD;
          -  No serious underlying medical condition, at the judgment of the investigator, which&#xD;
             could impair the ability of the patient to participate in the trial (e.g., active&#xD;
             autoimmune disease or uncontrolled diabetes)&#xD;
&#xD;
          -  No malignancy within the past 3 years except for adequately treated carcinoma in situ&#xD;
             of the cervix or localized nonmelanoma skin cancer&#xD;
&#xD;
          -  No psychiatric disorder precluding understanding information of trial-related topics,&#xD;
             giving informed consent, or interfering with compliance for oral drug intake&#xD;
&#xD;
          -  No known hypersensitivity to trial drugs or hypersensitivity to any other components&#xD;
             of the trial drugs&#xD;
&#xD;
          -  No known HIV positivity or hepatitis C infection&#xD;
&#xD;
          -  No serological evidence of current or past hepatitis B infection, unless the&#xD;
             serological findings are clearly due to vaccination&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic therapy for this disease&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior treatment in another clinical trial&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent corticosteroids unless administered as&#xD;
             prophylaxis in at-risk patients for ≤ 3 days or at a dose equivalent to prednisone ≤&#xD;
             15 mg/day, for indications other than lymphoma or lymphoma-related symptoms&#xD;
&#xD;
          -  No concomitant drugs contraindicated for use with the trial drugs&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva K. Kimby, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felicitas Hitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjorn Ostenstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland Hospital - University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sorlandet Sykehus HF Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger HF</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway - Tromso</name>
      <address>
        <city>Tromso</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Linkoping</name>
      <address>
        <city>Linkoping</city>
        <zip>S-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderbyn Hospital</name>
      <address>
        <city>Lulea</city>
        <zip>95128</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvall Hospital</name>
      <address>
        <city>Sundsvall</city>
        <zip>85186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands University Hospital</name>
      <address>
        <city>Umea</city>
        <zip>S-90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis - Brig</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

